-+ 0.00%
-+ 0.00%
-+ 0.00%

BullFrog AI publishes shareholder letter updating on Q2 2026 outlook

PUBT·04/13/2026 20:39:06
Listen to the news
BullFrog AI publishes shareholder letter updating on Q2 2026 outlook
  • BullFrog AI published shareholder letter outlining commercial ramp plans with global pharmaceutical, biotechnology partners.
  • First commercial feasibility agreement signed March 30, 2026 with a top 5 global pharma company, focused on identifying drug targets in major depressive disorder.
  • Deal includes milestone payments tied to deliverables, option for partner to secure exclusive rights to final selected target candidate for R&D.
  • Financing completed in late March 2026 lifted stockholders’ equity above $2.5 million, supporting Nasdaq listing compliance.
  • Runway expected to extend into late 2027 based on current cash burn-rate.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BullFrog AI Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-016378), on April 13, 2026, and is solely responsible for the information contained therein.